α-肾上腺素能受体阻滞剂治疗男性下尿路症状的疗效
Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms.
作者信息
Roehrborn Claus G
机构信息
Department of Urology, University of Texas Southwestern Medical Center Dallas, TX.
出版信息
Rev Urol. 2009 Fall;11(Suppl 1):S1-8.
Abstract
Male lower urinary tract symptoms (LUTS) are one of the most common causes for a consultation with a health care provider, and one of the most common causes of male LUTS is benign prostatic hyperplasia (BPH). In recent decades, medical therapy has established itself as viable and cost effective for the majority of men. For the treatment of male LUTS in the United States, the 5 currently available alpha-adrenergic receptor blockers are alfuzosin, doxazosin, silodosin, terazosin, and tamsulosin. alpha-Blockers remain one of the mainstays in the treatment of male LUTS and clinical BPH. They exhibit an early onset of efficacy (within less than 1 week) with regard to both symptoms and flow rate improvement, maintain such improvements in open-label and controlled trials for up to 5 years, and have been shown to prevent symptomatic progression.
摘要
男性下尿路症状（LUTS）是患者咨询医疗服务提供者的最常见原因之一，而良性前列腺增生（BPH）是男性LUTS的最常见原因之一。近几十年来，药物治疗已成为大多数男性可行且具有成本效益的治疗方法。在美国，目前可用的5种α-肾上腺素能受体阻滞剂用于治疗男性LUTS，分别是阿夫唑嗪、多沙唑嗪、西洛多辛、特拉唑嗪和坦索罗辛。α-阻滞剂仍然是治疗男性LUTS和临床BPH的主要药物之一。它们在症状和流速改善方面起效早（不到1周），在开放标签和对照试验中可将这些改善维持长达5年，并且已被证明可预防症状进展。
相似文献
1
Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms.α-肾上腺素能受体阻滞剂治疗男性下尿路症状的疗效
Rev Urol. 2009 Fall;11(Suppl 1):S1-8.
2
The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.α受体阻滞剂治疗良性前列腺增生所致下尿路症状的诊断与治疗：聚焦于西洛多辛
Clin Drug Investig. 2015 Feb;35 Suppl 1:7-18. doi: 10.1007/s40261-014-0257-3.
3
A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.一项关于阿夫唑嗪、坦索罗辛和西洛多辛治疗良性前列腺增生症疗效和耐受性的随机、对照、开放标签研究。
Indian J Pharmacol. 2016 Mar-Apr;48(2):134-40. doi: 10.4103/0253-7613.178825.
4
Alpha blockers for the treatment of benign prostatic hyperplasia.用于治疗良性前列腺增生的α受体阻滞剂。
Rev Urol. 2007 Fall;9(4):181-90.
5
Silodosin in the treatment of benign prostatic hyperplasia.西洛多辛治疗良性前列腺增生症。
Drug Des Devel Ther. 2010 Oct 27;4:291-7. doi: 10.2147/DDDT.S10428.
6
α-Blockers for benign prostatic hyperplasia: the new era.α 受体阻滞剂治疗良性前列腺增生症：新时代。
Curr Opin Urol. 2012 Jan;22(1):7-15. doi: 10.1097/MOU.0b013e32834d9bfd.
7
8
Finasteride for benign prostatic hyperplasia.非那雄胺用于良性前列腺增生症。
Cochrane Database Syst Rev. 2010 Oct 6;2010(10):CD006015. doi: 10.1002/14651858.CD006015.pub3.
9
The role of combination medical therapy in benign prostatic hyperplasia.联合药物治疗在良性前列腺增生中的作用。
Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51.
10
Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH - a double-blind randomized trial.坦索罗辛、阿夫唑嗪或西洛多辛单药治疗良性前列腺增生所致下尿路症状的安全性和有效性——一项双盲随机试验
Cent European J Urol. 2017 Jun 30;70(2):148-153. doi: 10.5173/ceju.2017.924. Epub 2017 Jun 7.
引用本文的文献
1
A comparative study of mirabegron versus doxazosin in improving ureteral stent-related dysfunction.米拉贝隆与多沙唑嗪改善输尿管支架相关功能障碍的比较研究。
World J Urol. 2025 May 13;43(1):299. doi: 10.1007/s00345-025-05663-9.
2
The Effect of Long-Term Tamsulosin Monotherapy and Tamsulosin - Dutasteride Combination Therapy on PKC-α Enzyme Expression in Prostate Stromal Tissue.长期坦索罗辛单药治疗及坦索罗辛 - 度他雄胺联合治疗对前列腺基质组织中蛋白激酶C-α（PKC-α）酶表达的影响
Med Arch. 2023;77(6):446-450. doi: 10.5455/medarh.2023.77.446-450.
3
Pharmacological and interventional treatment of benign prostatic obstruction: An evidence-based comparative review.良性前列腺梗阻的药物及介入治疗：一项基于证据的比较性综述
BJUI Compass. 2021 Feb 3;2(4):238-259. doi: 10.1002/bco2.74. eCollection 2021 Jul.
4
Male Lower Urinary Tract Dysfunction: An Underrepresented Endpoint in Toxicology Research.男性下尿路功能障碍：毒理学研究中一个未得到充分关注的终点指标。
Toxics. 2022 Feb 16;10(2):89. doi: 10.3390/toxics10020089.
5
Beneficial Extracardiac Effects of Cardiovascular Medications.心血管药物的有益心脏外作用。
Curr Cardiol Rev. 2022;18(2):e151021197270. doi: 10.2174/1573403X17666211015145132.
6
Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans.CYP2D6和CYP3A5基因多态性对坦索罗辛在人体内稳态药代动力学及血流动力学效应的影响。
Eur J Clin Pharmacol. 2018 Oct;74(10):1281-1289. doi: 10.1007/s00228-018-2501-x. Epub 2018 Jun 13.
7
Efficacy and safety of silodosin in the treatment of lower urinary tract symptoms in elderly men taking antihypertensive medications.西洛多辛治疗服用抗高血压药物的老年男性下尿路症状的疗效和安全性。
Prostate Int. 2017 Sep;5(3):113-118. doi: 10.1016/j.prnil.2017.02.001. Epub 2017 Feb 20.
8
Impact of oral capsule of on alleviating urinary symptoms in men with benign prostatic hyperplasia; a randomized clinical trial.[某种药物]口服胶囊对缓解良性前列腺增生男性患者尿路症状的影响；一项随机临床试验。 （注：原文中“oral capsule of ”部分缺失具体药物名称）
J Renal Inj Prev. 2016 Dec 18;6(2):127-131. doi: 10.15171/jrip.2017.25. eCollection 2017.
9
The use of primary and secondary doxazosin XL (8 mg) in the treatment of benign prostate hyperplasia: Is there a new approach in the event of alpha-blocker failure?使用首剂及次剂多沙唑嗪控释片（8毫克）治疗良性前列腺增生：在α受体阻滞剂治疗失败的情况下是否存在新的治疗方法？
Turk J Urol. 2014 Mar;40(1):35-9. doi: 10.5152/tud.2014.31384.
10
Isoform-specific dynamic translocation of PKC by α1-adrenoceptor stimulation in live cells.活细胞中α1-肾上腺素能受体刺激引起的蛋白激酶C（PKC）亚型特异性动态易位
Biochem Biophys Res Commun. 2015 Sep 25;465(3):464-70. doi: 10.1016/j.bbrc.2015.08.040. Epub 2015 Aug 12.
本文引用的文献
1
Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.西洛多辛缓解良性前列腺梗阻的疗效：前瞻性压力流研究
J Urol. 2009 Dec;182(6):2831-5. doi: 10.1016/j.juro.2009.08.030. Epub 2009 Oct 17.
2
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.度他雄胺和坦索罗辛联合治疗对有症状的良性前列腺增生症男性临床结局的影响：来自 CombAT 研究的 4 年结果。
Eur Urol. 2010 Jan;57(1):123-31. doi: 10.1016/j.eururo.2009.09.035. Epub 2009 Sep 19.
3
Alpha blockers prior to removal of a catheter for acute urinary retention in adult men.成年男性急性尿潴留患者拔除导尿管前使用α受体阻滞剂。
Cochrane Database Syst Rev. 2009 Oct 7(4):CD006744. doi: 10.1002/14651858.CD006744.pub2.
4
Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study.西洛多辛治疗良性前列腺增生症的症状：一项 9 个月、开放标签延伸研究。
Urology. 2009 Dec;74(6):1318-22. doi: 10.1016/j.urology.2009.06.072. Epub 2009 Oct 7.
5
Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia.治疗良性前列腺增生的新型α1A-肾上腺素能受体选择性拮抗剂——西洛多辛的尿动力学效应。
Neurourol Urodyn. 2010 Apr;29(4):558-62. doi: 10.1002/nau.20802.
6
Medical therapy to facilitate the passage of stones: what is the evidence?促进结石排出的医学疗法：证据是什么？
Eur Urol. 2009 Sep;56(3):455-71. doi: 10.1016/j.eururo.2009.06.012. Epub 2009 Jun 21.
7
Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.高选择性α1A肾上腺素能受体拮抗剂西洛多辛对有良性前列腺增生体征和症状男性的快速疗效：两项3期研究的汇总结果
J Urol. 2009 Jun;181(6):2634-40. doi: 10.1016/j.juro.2009.02.034. Epub 2009 Apr 16.
8
BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.良性前列腺增生进展：来自MTOPS、ALTESS、COMBAT和ALF-ONE的概念及关键认识。
BJU Int. 2008 Mar;101 Suppl 3:17-21. doi: 10.1111/j.1464-410X.2008.07497.x.
9
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms.α1肾上腺素能受体亚型与下尿路症状
Int J Urol. 2008 Mar;15(3):193-9. doi: 10.1111/j.1442-2042.2007.01956.x.
10
A systematic review of medical therapy to facilitate passage of ureteral calculi.促进输尿管结石排出的药物治疗系统评价。
Ann Emerg Med. 2007 Nov;50(5):552-63. doi: 10.1016/j.annemergmed.2007.05.015. Epub 2007 Aug 3.
Zotero 插件